Novel role for CRK adaptor proteins as essential components of SRC/FAK signaling for epithelial–mesenchymal transition and colorectal cancer aggressiveness. Issue 6 (16th March 2020) - Franke, Fabian C.
Abstract : Epithelial–mesenchymal transition (EMT) is a cell plasticity process required for metastasis and chemoresistance of carcinoma cells. We report a crucial role of the signal adaptor proteins CRK and CRKL in promoting EMT and tumor aggressiveness, as well as resistance against chemotherapy in colorectal and pancreatic carcinoma. Genetic loss of either CRKL or CRK partially counteracted EMT in three independent cancer cell lines. Strikingly, complete loss of the CRK family shifted cells strongly toward the epithelial phenotype. Cells exhibited greatly increased E‐cadherin and grew as large, densely packed clusters, completely lacked invasiveness and the ability to undergo EMT induced by cytokines or genetic activation of SRC. Furthermore, CRK family‐deficiency significantly reduced cell survival, proliferation and chemoresistance, as well as ERK1/2 phosphorylation and c‐MYC protein levels. In accordance, MYC‐target gene expression was identified as novel hallmark process positively regulated by CRK family proteins. Mechanistically, CRK proteins were identified as pivotal amplifiers of SRC/FAK signaling at focal adhesions, mediated through a novel positive feedback loop depending on RAP1. Expression of the CRK family and the EMT regulator ZEB1 was significantly correlated in samples from colorectal cancer patients, especially in invasive regions. Further, high expression of CRK family genes was significantly associated with reduced survival in locally advanced colorectal cancer, as well as in pan‐cancer datasets from the TCGA project. Thus, CRK family adaptor proteins are promising therapeutic targets to counteract EMT, chemoresistance, metastasis formation and minimal residual disease. As proof of concept, CRK family‐mediated oncogenic signaling was successfully inhibited by a peptide‐based inhibitor. Abstract : What's new? Epithelial‐mesenchymal transition (EMT) is an essential prerequisite for metastatic spread and resistance against chemotherapy, which cause major clinical problems in colorectal and other carcinomas. CRK adaptor proteins are known as downstream effectors of SRC/FAK kinases. Here, the authors demonstrate that CRK proteins mediate the EMT‐associated phenotypes of colorectal cancer aggressiveness, act as novel feedback amplifiers of SRC/FAK kinase signaling, and induce c‐MYC signaling. The findings highlight CRK family adaptor proteins as promising therapeutic targets to counteract EMT, chemoresistance, metastasis formation, and minimal residual disease. Moreover, as proof of concept, CRK family‐mediated oncogenic signaling was successfully inhibited by a peptide‐based inhibitor.